XTL Biopharmaceuticals Announces Corporate Presentations to be Held Today, Monday, November 6, 2006
06 November 2006 - 7:20PM
PR Newswire (US)
Rodman & Renshaw 8th Annual Healthcare Conference NEW YORK,
November 6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced today that Ron Bentsur,
the Company's Chief Executive Officer, is scheduled to present at
the Rodman & Renshaw 8th Annual Healthcare Conference and the
CIBC World Markets 17th Annual Healthcare Conference. Both
presentations will be held today, as follows: Rodman & Renshaw
8th Annual Healthcare Conference - 10:15 am EST at the New York
Palace Hotel in New York City. A live webcast of Mr. Bentsur's
presentation will be available at
http://www.wsw.com/webcast/rrshq10/xtl.ln/. An archived version of
the webcast will be available following the conclusion of the live
presentation. CIBC World Markets 17th Annual Healthcare Conference
- 12:55 pm EST at the Waldorf Astoria Hotel in New York City. A
live webcast of Mr. Bentsur's presentation will be available at
http://www.veracast.com/webcasts/cibcwm/healthcare06/54109276.cfm.
An archived version of the webcast will be available following the
conclusion of the live presentation. ABOUT XTL BIOPHARMACEUTICALS
LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the
acquisition, development and commercialization of therapeutics for
the treatment of infectious diseases, with a focus on hepatitis C.
XTL is developing XTL-2125 - a small molecule, non-nucleoside
inhibitor of the hepatitis C virus polymerase. XTL-2125 is
currently in a Phase 1 clinical trial in patients with chronic
hepatitis C. XTL is also developing XTL-6865 - a combination of two
monoclonal antibodies against the hepatitis C virus - presently in
Phase 1 clinical trials in patients with chronic hepatitis C. XTL's
hepatitis C pipeline also includes several families of pre-clinical
hepatitis C small molecule inhibitors. XTL also has an active
in-licensing and acquisition program designed to identify and
acquire additional drug candidates. XTL is publicly traded on the
NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ:
XTLB)(LSE:XTL)(TASE:XTL). Contact: Ron Bentsur, Chief Executive
Officer Tel: +1-(212)-531-5960 DATASOURCE: XTL Biopharmaceuticals
Ltd CONTACT: Contact: Ron Bentsur, Chief Executive Officer, Tel:
+1-(212)-531-5960
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024